Hydrochloorthiazide and Hypernatriaemie

Hypernatraemia and Diuretics in Intensive Care Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01974739

Enrollment

Registered

2013-11-04

Start date

2013-09-30

Completion date

2015-05-31

Last updated

2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypernatraemia

Keywords

intensive care, diuretics

Brief summary

Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Interventions

DRUGHydrochloorthiazide

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* sodium \> 142

Exclusion criteria

* no informed consent

Design outcomes

Primary

Measure	Time frame	Description
sodium level	7 days	a decrease of 5 mmol/L sodium in plama

Secondary

Measure	Time frame	Description
time hypernatraemia	7 days	decrease of duration high sodium level in plasma

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026